{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:01:41Z","timestamp":1780614101753,"version":"3.54.1"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>As an angiogenesis inhibitor, bevacizumab has been investigated in combination with different chemotherapeutic agents, achieving an established role for metastatic cancer treatment. However, potential synergic anti-angiogenic effects of hyperthermia have not tested to date in literature. The aim of our study was to analyze efficacy, safety, and survival of anti-angiogenic-based chemotherapy associated to regional deep capacitive hyperthermia (HT) in metastatic cancer patients. Twenty-three patients with metastatic colorectal (n = 16), ovarian (n = 5), and breast (n = 2) cancer were treated with HT in addition to a standard bevacizumab-based chemotherapy regimen. Treatment response assessment was performed, according to the modified Response Evaluation Criteria for Solid Tumors (mRECIST), at 80 days (timepoint-1) and at 160 days (timepoint-2) after therapy. Disease Response Rate (DRR), considered as the proportion of patients who had the best response rating (complete response (CR), partial response (PR), or stable disease (SD)), was assessed at timepoint-1 and timepoint-2. Chi-squared for linear trend test was performed to evaluated the association between response groups (R\/NR) and the number of previous treatment (none, 1, 2, 3), number of chemotherapy cycles (&lt;6, 6, 12, &gt;12), number of hyperthermia sessions (&lt;12, 12, 24, &gt;24), and lines of chemotherapy (I, II). Survival curves were estimated by Kaplan-Meier method. DRR was 85.7% and 72.2% at timepoint-1 and timepoint-2, respectively. HT was well tolerated without additional adverse effects on chemotherapy-related toxicity. Chi-squared for linear trend test demonstrated that the percentage of responders grew in relation to the number of chemotherapy cycles (p = 0.015) and to number of HT sessions (p &lt; 0.001) performed. Both overall survival (OS) and time to progression (TTP) were influenced by the number of chemotherapy cycles (p &lt; 0.001) and HT sessions (p &lt; 0.001) performed. Our preliminary data, that need to be confirmed in larger studies, suggest that the combined treatment of bevacizumab-based chemotherapy with HT has a favorable tumor response, is feasible and well tolerated, and offers a potentially promising option for metastatic cancer patients.<\/jats:p>","DOI":"10.3390\/ijms18071458","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T10:55:45Z","timestamp":1499338545000},"page":"1458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Girolamo","family":"Ranieri","sequence":"first","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0168-8551","authenticated-orcid":false,"given":"Cristina","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"},{"name":"Nuclear Medicine Unit, D.I.M., University of Bari \u201cAldo Moro\u201d, Piazza G. Cesare 11, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Di","family":"Palo","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"},{"name":"Nuclear Medicine Unit, D.I.M., University of Bari \u201cAldo Moro\u201d, Piazza G. Cesare 11, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Marech","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Porcelli","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Falagario","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Ritrovato","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ramunni","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0128-9745","authenticated-orcid":false,"given":"Margherita","family":"Fanelli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, D.I.M., University of Bari \u201cAldo Moro\u201d, Piazza G. Cesare 11, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rubini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, D.I.M., University of Bari \u201cAldo Moro\u201d, Piazza G. Cesare 11, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmo Damiano","family":"Gadaleta","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"204","author":"Dvorak","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Saponaro, C., Malfettone, A., Ranieri, G., Danza, K., Simone, G., Paradiso, A., and Mangia, A. (2013). VEGF, HIF-1\u03b1 Expression and MVD as an Angiogenic Network in Familial Breast Cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053070"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23024","DOI":"10.3390\/ijms151223024","article-title":"Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer","volume":"15","author":"Kristensen","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3816\/CCC.2006.n.042","article-title":"Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor\/5-fluorouracil\/bevacizumab versus leucovorin\/5-fluorouracil\/bevacizumab as initial treatment for metastatic colorectal carcinoma","volume":"6","author":"Saif","year":"2006","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1525-7304(11)70220-0","article-title":"Bevacizumab, when added to paclitaxel\/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: Preliminary results from the ECOG 4599 trial","volume":"6","author":"Tyagi","year":"2005","journal-title":"Clin. Lung Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ygyno.2004.12.001","article-title":"Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer","volume":"96","author":"Monk","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2006.06.014","article-title":"The role of bevacizumab in ovarian cancer\u2014An evolving story","volume":"102","author":"Aghajanian","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_11","first-page":"37","article-title":"Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: A review","volume":"2","author":"Pories","year":"2010","journal-title":"Breast Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.2174\/138161212802430468","article-title":"Target-based anti-angiogenic therapy in breast cancer","volume":"18","author":"Wehland","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/978-3-642-82955-0_5","article-title":"Hyperthermia and drugs","volume":"104","author":"Engelhardt","year":"1987","journal-title":"Recent Results Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/02656736.2012.695428","article-title":"Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer","volume":"28","author":"Ishikawa","year":"2012","journal-title":"Int. J. Hyperth."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3892\/ol.2014.2376","article-title":"Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study","volume":"8","author":"Infusino","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_17","unstructured":"(2017, May 22). American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. Available online: http:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2004.05.063."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1074\/jbc.M210063200","article-title":"Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability","volume":"278","author":"Lee","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2710.2007.00800.x","article-title":"Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer","volume":"32","author":"Lipp","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_23","unstructured":"Annex, I. (2017, June 07). Summary of Product Characteristics. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000582\/WC500029271.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00066-011-1145-x","article-title":"ESHO Technical Committee in the Interdisciplinary Working Group Hyperthermia (IAH) in the German Cancer Society: Quality assurance for clinical studies in regional deep hyperthermia","volume":"187","author":"Bruggmoser","year":"2011","journal-title":"Strahlenther. Onkol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer."},{"key":"ref_26","first-page":"8910","article-title":"Possible biological and translational significance of mast cells density in colorectal cancer","volume":"20","author":"Marech","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevaci- zumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for her2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1758834012467661","article-title":"Bevacizumab and ovarian cancer","volume":"5","author":"Garcia","year":"2013","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1517\/14728222.2012.725047","article-title":"Tumor endothelial markers as a target in cancer","volume":"16","author":"Ribatti","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/14728214.11.4.635","article-title":"Therapeutic options to target angiogenesis in human malignancies","volume":"11","author":"Herbst","year":"2006","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_36","first-page":"1500","article-title":"Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism","volume":"63","author":"Roca","year":"2003","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0973-1482.25848","article-title":"Hyperthermia today: Electric energy, a new opportunity in cancer treatment","volume":"2","author":"Fiorentini","year":"2006","journal-title":"J. Cancer Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1525-1438.2007.00886.x","article-title":"A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"17","author":"Micha","year":"2007","journal-title":"Int. J. Gynecol. Cancer."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/7\/1458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:41:41Z","timestamp":1760208101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/7\/1458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"alternative-id":["ijms18071458"],"URL":"https:\/\/doi.org\/10.3390\/ijms18071458","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]}}}